- Home
- VSNT vs MIRM Comparison
VSNT vs MIRM Comparison
Compare VSNT & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSNT | MIRM |
|---|---|---|
| Founded | 2025 | 2018 |
| Country | United States | United States |
| Employees | 4400 | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 7.2B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | VSNT | MIRM |
|---|---|---|
| Price | $35.88 | $114.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $43.67 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 1.7M | 639.9K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | N/A | $26.22 |
| Revenue Next Year | N/A | $22.04 |
| P/E Ratio | $3.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.17 | $50.25 |
| 52 Week High | $45.58 | $130.00 |
Technical Indicators
Market Signals| Indicator | VSNT | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 45.39 | 47.83 |
| Support Level | $34.91 | $87.93 |
| Resistance Level | $36.79 | $114.99 |
| Average True Range (ATR) | 0.96 | 4.52 |
| MACD | 0.15 | -1.76 |
| Stochastic Oscillator | 56.29 | 20.84 |
Price Performance
Historical ComparisonAbout VSNT Versant Media Group Inc. Class A Common Stock
Versant Media Group Inc is an independent media company comprised of NBCUniversal's cable television networks, including USA Network, CNBC, MSNBC, Oxygen, SYFY, and Golf Channel, along with complementary digital assets Fandango, Rotten Tomatoes, GolfNow, GolfPass, and SportsEngine.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.